ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...

Access to innovative medicines remains a critical issue in healthcare. Teva Pharmaceuticals is tackling this challenge head-on, driving scientific innovation to deliver high-quality medicines that ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...

Granules India received tentative USFDA approval for Amphetamine Extended-Release Orally Disintegrating Tablets, offering 180 ...

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

Glycerol phenylbutyrate oral liquid is indicated for the chronic management of patients with urea cycle disorders. Sims added, "It expands access for patients and providers, and reinforces our ...

Price erosion in several mature molecules has continued through 2025 and into early 2026 ...

WASHINGTON (Reuters) - Cheaper, generic versions of more complex protein-based drugs will need more data than simpler compounds to prove their safety and effectiveness, a U.S. Food and Drug ...

While drug pricing has been a consistent focus for policymakers concerned about access to medicine, another significant barrier to care has grown: drug shortages. Drug shortages have become more ...